Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Ambrisentan plus Spironolactone[2] Ambrisentan,
Spironolactone		[2] Spironolactone ,
Ambrisentan 💬		[2] EDNRA,
NR3C2 💬		[8] Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[1] 86 💬
2Spironolactone[1] Spironolactone[1] Spironolactone 💬[1] NR3C2 💬[1] Aldosterone-regulated sodium reabsorption 💬[8] 46, 58, 67, 86, 113, 210, 218, 225 💬
3Spironolactone (drug)[1] Spironolactone[1] Spironolactone 💬[1] NR3C2 💬[1] Aldosterone-regulated sodium reabsorption 💬[1] 210 💬
4Spironolactone and conivaptan[2] Conivaptan,
Spironolactone		[2] Spironolactone ,
Conivaptan 💬		[3] AVPR1A,
AVPR2,
NR3C2 💬		[6] Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬[1] 86 💬
5Spironolactone captopril carvedilol[3] Captopril,
Carvedilol,
Spironolactone		[3] Captopril ,
Carvedilol ,
Spironolactone 💬		[7] ACE,
ADRA1A,
ADRA1B,
ADRA1D,
ADRB1,
ADRB2,
NR3C2 💬		[19] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Chagas disease, Chemical carcinogenesis - receptor activation, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[1] 86 💬